Orexin-A vs Noopept
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) — benefits, dosing, side effects, research data, and where to buy.
| Property | Orexin-A | Noopept |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | Hypocretin-1 (Orexin-A) | N-phenylacetyl-L-prolylglycine ethyl ester |
| Molecular Weight | 3562 Da | 318.37 Da |
| Half-Life | Minutes to <1 hour | 20-30 minutes |
| Amino Acids | 33 | N/A |
| Typical Dose | Research-only; no validated human dose | 10-30 mg/day |
| Route | Intracerebroventricular/Intranasal | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 60 |
| Research Status | Pre-clinical | Clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Noopept Benefits
- ✓memory recall
- ✓learning efficiency
- ✓attention support
- ✓neurotrophic signaling
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Noopept Dosing
oral research use|10-30 mg per day in human studies|divided or single daily dosing
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Noopept Side Effects
- ⚠headache
- ⚠irritability
- ⚠sleep disturbance
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Noopept
Noopept has been reported to increase NGF/BDNF-related signaling and improve performance in tasks involving learning and recall. Evidence includes preclinical studies and small human studies, but the overall literature is still modest compared with mainstream cognitive drugs.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.